lundi 30 mars 2020

Onco Actu du 30 mars 2020


1.1 BIOLOGIE - GÉNOME



Study shows recurrent alterations in prostate cancer in Chinese patients differ from those in the west [Medical Xpress]











2. ETIOLOGIE



A mutational signature that can be made by a bacterium arises in human colon cancer [Nature]











5.12 IMMUNOTHÉRAPIES



New drugs that unleash the immune system on cancers may backfire, fueling tumor growth [Science]











5.12.6 IMMUNOTHÉRAPIES - AMM



AstraZeneca gets a green light on Imfinzi for small-cell lung cancer — setting the stage for a battle with Roche's Tecentriq [EndPoints]










Imfinzi approved in the US for extensive-stage small cell lung cancer [AstraZeneca]











AstraZeneca's lung cancer treatment gets FDA nod [Reuters]











5.17 TRAITEMENTS - RADIOTHÉRAPIE



How Should Radiation Oncologists Manage Prostate Cancer Patients During the COVID-19 Pandemic? [University of Michigan]











6.15 LUTTE CONTRE LES CANCERS - COVID-19



For CAR-T, coronavirus brings uneven impact to studies, treatment [Biopharma Dive]











AVEO Oncology and Biodesix to Discontinue CyFi-2 Study of Ficlatuzumab in Relapsed and Refractory AML in Response to Public Health Crisis [Aveo]











Should Cancer Treatment Be Continued During the Pandemic? A Case-by-Case Discussion Is Required [ESMO]











Coronavirus shuts down trials of drugs for multiple other diseases [Nature]










6.6 PUBLICATIONS, POLITIQUES SCIENTIFIQUES



Boosting the signal in scientific talks [Nature]